DelveInsight’s “Presbyopia Market” report provides a thorough comprehension of the Presbyopia, historical and forecasted epidemiology, and the Presbyopia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Presbyopia market report also proffers an analysis of the current Presbyopia treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the key takeaways of the Presbyopia Market Research Report
For further information on Market Impact by Therapies, visit: Presbyopia Treatment Market Trends
Presbyopia is the gradual loss of near-focusing ability that occurs with age. Presbyopia is caused partly due to age-related changes in the proteins within the eye lens, due to which it becomes thicker, more challenging, and less flexible. This loss of flexibility affects the lens’s ability to refract light rays, which affects the eye’s capacity to focus.
Presbyopia mainly affects the age-group between 40 and 60 as the eyes’ lenses naturally lose elasticity due to the ageing process. According to DelveInsight’s analysts, the total Presbyopia prevalent cases in the 7MM were 286,994,105 cases in 2020. These cases are expected to grow with a nominal CAGR in the forecast period 2021–2030.
The Presbyopia Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Get a sample copy of this report: Presbyopia Market Landscape
Presbyopia Treatment Market
The Presbyopia treatment goal is to compensate for the inability of the eyes to focus on nearby objects. Currently, the market is mainly dominated by non-pharmacological treatment options such as corrective eyeglasses (spectacle lenses) or contact lenses, refractive surgery, or lens implants. Current clinical management of Presbyopia includes off-label treatment using nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The most commonly used agents are Pilocarpine, Carbachol, Aceclidine, Brimonidine, Nepafenac, and others.
Presbyopia pharmacological treatment is based on using ophthalmic drops for improving near vision. Many different modifications, including the combination of two parasympathomimetics and an NSAID, two parasympathomimetics and one parasympatholytic, carbachol 2.25% with brimonidine 0.2%, and a variety of pilocarpine 0.247%, phenylephrine 0.78%, polyethylene glycol 0.09%, nepafenac 0.023%, pheniramine 0.034%, and naphazoline 0.003% were studied. A different strategy based on lipoic acid derivative drops aims to soften the crystalline lens.
In the US and Europe, some tempering components of the drug formulation also used as an off-label treatment in Presbyopia are brimonidine to reduce ciliary muscle contraction, bromfenac, diclofenac, and dexamethasone to minimise inflammation and ciliary muscle contraction, phenylephrine to decrease ciliary muscle contraction, naphazoline to minimise redness, tropicamide to reduce accommodation, and polyethylene glycol to increase comfort.
The companies have initiated clinical trials to investigate new treatment options and manage disease in the 7MM.
Presbyopia Emerging Therapies Along with Key Players
And several others.
In conclusion, Presbyopia Market Growth will surge due to market drivers such as an increase in the geriatric population, increasing research in pharmaceutical treatment, and an upsurge in the launch of products; on the other hand, there are a few impediments such as rising healthcare costs, lack of accessibility of eye care services, and shortage of trained ophthalmologists will hamper the growth.
Scope of the Presbyopia Market Insight Report
Table of Contents
1
Presbyopia Key Insights
2
Presbyopia Report Introduction
3
Presbyopia Market Overview at a Glance
4
Executive Summary of Presbyopia
5
Presbyopia Market: Future Perspective
6
Presbyopia Epidemiology and Patient Population
7
Presbyopia Disease Background and Overview
8
Presbyopia Diagnosis
9
Early Detection and Prevention of Presbyopia
10
Presbyopia Current Treatment Practices
11
Guidelines of Presbyopia
12
12.1
The United States
12.2
EU5 Countries
12.2.1
Germany
12.2.2
France
12.2.3
Italy
12.2.4
Spain
12.2.5
The United Kingdom
12.3
Japan
13
Presbyopia Patient Journey
14
Key Endpoints in Presbyopia Clinical Trials
15
Presbyopia Emerging Drugs
15.1
AGN-190584: Allergan (acquired by AbbVie)
15.2
MicroLine (Pilocarpine Ophthalmic): Eyenovia
15.3
PresbiDrops (CSF-1): Orasis Pharmaceuticals
15.4
Nyxol (Phentolamine Mesylate): Ocuphire Pharma
15.5
UNR844 (Lipoic acid choline ester; formerly known as EV06): Novartis
15.6
VTI-001 (Brimochol): Visus Therapeutics
15.7
AGN-241622: Allergan (acquired by AbbVie)
16
Conjoint Analysis of Presbyopia
17
7MM Presbyopia Market Analysis
17.1
The United States Presbyopia Market Size
17.2
EU-5 Presbyopia Market Size
17.2.1
Germany Market Size
17.2.2
France Market Size
17.2.3
Italy Market Size
17.2.4
Spain Market Size
17.2.5
The United Kingdom Market Size
17.3
Japan Presbyopia Market Size
18
Presbyopia Market Access and Reimbursement
19
KOL Views
20
Presbyopia Market Drivers
21
Presbyopia Market Barriers
22
SWOT Analysis of Presbyopia
23
Presbyopia Unmet Needs
24
Appendix
25
DelveInsight Capabilities
26
Disclaimer
27
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/presbyopia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr